We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA
Accepted date
Oct-2025
Active ingredients
pembrolizumab
Proposed indication
Keytruda (pembrolizimab) is proposed to be used together with other cancer treatments (paclitaxel, and/or bevacizumab) to help treat certain types of ovarian, fallopian tube, or peritoneal cancer. This treatment is for people whose cancer has not responded to platinum-based medicines and who have already tried one or two other treatments.
Application type
C (new indication)
Publication date
Oct-2025